- Home
- RXST vs WVE Comparison
RXST vs WVE Comparison
Compare RXST & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- WVE
- Stock Information
- Founded
- RXST 1997
- WVE 2012
- Country
- RXST United States
- WVE Singapore
- Employees
- RXST N/A
- WVE N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- RXST Health Care
- WVE Health Care
- Exchange
- RXST Nasdaq
- WVE Nasdaq
- Market Cap
- RXST 1.0B
- WVE 939.3M
- IPO Year
- RXST 2021
- WVE 2015
- Fundamental
- Price
- RXST $13.06
- WVE $6.59
- Analyst Decision
- RXST Buy
- WVE Strong Buy
- Analyst Count
- RXST 10
- WVE 11
- Target Price
- RXST $38.50
- WVE $20.91
- AVG Volume (30 Days)
- RXST 1.1M
- WVE 1.7M
- Earning Date
- RXST 05-07-2025
- WVE 05-08-2025
- Dividend Yield
- RXST N/A
- WVE N/A
- EPS Growth
- RXST N/A
- WVE N/A
- EPS
- RXST N/A
- WVE N/A
- Revenue
- RXST $148,310,000.00
- WVE $104,939,000.00
- Revenue This Year
- RXST $24.14
- WVE N/A
- Revenue Next Year
- RXST $21.47
- WVE N/A
- P/E Ratio
- RXST N/A
- WVE N/A
- Revenue Growth
- RXST 46.70
- WVE N/A
- 52 Week Low
- RXST $13.50
- WVE $4.25
- 52 Week High
- RXST $66.54
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- RXST 32.41
- WVE 42.81
- Support Level
- RXST $13.72
- WVE $5.62
- Resistance Level
- RXST $15.41
- WVE $6.73
- Average True Range (ATR)
- RXST 0.90
- WVE 0.61
- MACD
- RXST 0.28
- WVE 0.07
- Stochastic Oscillator
- RXST 1.00
- WVE 34.84
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.